Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment